Isoorientin-Based GSK-3β Inhibitors for Selective Substrate Site Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GSK-3β inhibitors targeting the ATP site have limited selectivity, leading to off-target effects and safety concerns, and existing natural products like isoorientin face challenges in pharmaceutical applications due to lack of druggable potency.
Innovation Solution
Development of a new structural class of substrate-competitive GSK-3β inhibitors based on the isoorientin scaffold, with specific structural modifications that enhance binding to the substrate site, increasing potency and selectivity, and incorporating lipophilic amide analogues to improve membrane permeability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ATP-site directed GSK-3β inhibitors are used, then GSK-3β inhibition is achieved, but selectivity is limited leading to off-target effects
Solution Approach 1:
The patent extracts the inhibitor from the ATP site and relocates it to the substrate binding site of GSK-3β. This is achieved by designing compounds that specifically bind to the substrate domain rather than competing with ATP, thereby achieving selective inhibition without affecting other ATP-dependent kinases and eliminating off-target effects.
Solution Approach 2:
The patent introduces a peptide-mimetic intermediary that resembles the natural substrate sequence of GSK-3β. This intermediary acts as a mediator between the inhibitor and the enzyme, allowing specific recognition and binding to the substrate site through amino acid interactions, thereby achieving high selectivity for GSK-3β over other kinases.
2Reliability
If natural products like isoorientin are used as GSK-3β inhibitors, then some inhibitory activity is observed, but druggable potency is insufficient for pharmaceutical applications
Solution Approach 1:
The patent combines the natural product isoorientin scaffold with peptide-mimetic elements to create a composite inhibitor. This hybrid structure integrates the bioactive flavone core with substrate-like peptide sequences, thereby enhancing the inhibitory potency and pharmacological properties while maintaining the ability to bind specifically to the GSK-3β substrate site.
Solution Approach 2:
The patent modifies key parameters of the natural product isoorientin by introducing peptide-like functional groups and optimizing the molecular structure to improve binding affinity. These parameter changes include adjusting the peptide backbone conformation, adding specific amino acid side chains, and optimizing hydrophobic interactions to achieve druggable potency levels.
3Reliability
If substrate domain targeted inhibitors are developed, then selectivity is improved, but few such inhibitors have been reported indicating development challenges
Solution Approach 1:
The patent segments the inhibitor into distinct functional modules: a peptide-mimetic segment that interacts with the substrate binding pocket and a pharmacophore segment that provides stable binding. This segmentation allows for rational design and optimization of each component independently, thereby simplifying the development process while maintaining high selectivity.
Data Source
AI summary
Isoorientin analogues and related compounds that inhibit glycogen synthase kinase-3β activity are provided as are methods of using these compounds in the treatment of cognitive, neurodegenerative or neurological diseases or conditions, as well as cancer, obesity, diabetes, inflammatory or autoimmune disease, cardiovascular disorder, metabolic syndrome X, hair loss, severe acute respiratory syndrome coronavirus, cocaine addiction, dental caries, bone loss and glaucoma.